With the emergence of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the treatment of
type 2 diabetes mellitus (T2DM) has achieved a new milestone, of which the insulin …

Obesity is becoming increasingly prevalent in China and worldwide and is closely related to
the development of hypertension. The pathophysiology of obesity-associated hypertension …

Abstract Purpose of Review The moderate glucose-lowering effect of sodium glucose co-
transporter 2 (SGLT2) inhibitors is unlikely to explain SGLT2 inhibitor-mediated beneficial …

Abstract GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors (SGLT-2is) are novel
antidiabetic medications associated with considerable cardiovascular benefits therapying …

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors have both anti-diabetic and anti-
obesity effects. However, the precise mechanism of the anti-obesity effect remains unclear …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors facilitate urine glucose excretion by
reducing glucose reabsorption, leading to ameliorate glycemic control. While the main …

Abstract Purpose of the Review Hyperactivity of sympathetic nervous system (SNS) plays a
role in the development of arterial hypertension and heart failure, two co-morbidities …

The EMPA-REG OUTCOME study revealed that a sodium-glucose cotransporter 2 (SGLT2)
inhibitor, empagliflozin, can remarkably reduce cardiovascular (CV) mortality and heart …

Diabetes and obesity are growing problems worldwide and are associated with a range of
acute and chronic complications, including acute myocardial infarction (AMI) and stroke …

Sodium–glucose co-transporter 2 (SGLT2) inhibitors are a new family of antidiabetic drugs
that reduce blood glucose independent of insulin. In this review, we present the advantages …